In Brief This Week: Luminex, Genedrive, CoverMyTest, and More

NEW YORK (360Dx) – Luminex this week said that it recently began clinical studies for a gastrointestinal assay on the Verigene II, its sample-to-answer benchtop molecular diagnostic system in development. The Verigene II system contains the same core nanoparticle chemistry as the firm's current Verigene system. It consolidates four individual consumables into a single cartridge within a closed system for a simpler workflow, the firm said. At any time, the Verigene II fully automated system will support up to six modules for random access testing.